![]() |
Prostate Cancer |
Free Subscription
1 Acta Radiol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Prostate Cancer is free of charge.
SyMRI histogram analysis for diagnosing clinically significant prostate cancer.
Acta Radiol. 2025 Jun 18:2841851251349488. doi: 10.1177/02841851251349488.
PubMed
Abstract available
Acute toxicity of prostate cancer radiotherapy associated with late toxicity:
Acute toxicity following prostate cancer radiotherapy was statistically and
significantly associated with late toxicity in patient-reported quality-of-life
metrics.
Cancer. 2025;131:e35886.
PubMed
Using radiomics model for predicting extraprostatic extension with PSMA PET/CT
studies: a comparative study with the Mehralivand grading system.
Cancer Imaging. 2025;25:77.
PubMed
Abstract available
Analysis and characterization of extrachromosomal circular DNA in prostate
cancer: Potential biomarker discovery from urine, plasma, and tumor samples.
Cancer Lett. 2025;628:217875.
PubMed
Abstract available
Association of Homologous Recombination Repair Alterations With Outcomes in
Patients with Metastatic Hormone-Sensitive Prostate Cancer.
Clin Cancer Res. 2025 Jun 16. doi: 10.1158/1078-0432.CCR-25-1178.
PubMed
Abstract available
MRI capacity assessment for prostate cancer screening in five sites of Europe.
Eur J Radiol. 2025;190:112235.
PubMed
Abstract available
Discordance between prostate MRI and PSMA-PET/CT: the next big challenge for
primary prostate tumor assessment?
Eur Radiol. 2025;35:4043-4054.
PubMed
Abstract available
Outcomes of Salvage Robotic-assisted Radical Prostatectomy: High-volume
Multicentric Data from the European Association of Urology Robotic Urology
Section Scientific Working Group.
Eur Urol. 2025;88:103-113.
PubMed
Abstract available
Re: Rajal B. Shah, Gladell P. Paner, Liang Cheng, et al. Genitourinary Pathology
Society and International Society of Urological Pathology White Paper on Defining
Indolent Prostate Cancer: Call for a Multidisciplinary Approach. Eur Urol. In
press. htt
Eur Urol. 2025 Jun 12:S0302-2838(25)00331-8. doi: 10.1016/j.eururo.2025.
PubMed
Magnetic Resonance Imaging-based Biopsy Strategies in Prostate Cancer Screening:
A Systematic Review.
Eur Urol. 2025 Jun 12:S0302-2838(25)00341-0. doi: 10.1016/j.eururo.2025.
PubMed
Abstract available
Risk Model for Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
Int J Urol. 2025 Jun 16. doi: 10.1111/iju.70149.
PubMed
Abstract available
Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With
Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study.
Int J Urol. 2025 Jun 16. doi: 10.1111/iju.70154.
PubMed
Abstract available
Editorial Comment to "VIRMA Accelerates the Tumorigenesis of Prostate Cancer via
Regulating the m6A Modification of NSMCE2 to Eliminate the Generation of Reactive
Oxygen Species".
Int J Urol. 2025 Jun 16. doi: 10.1111/iju.70150.
PubMed
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic
Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II
Randomized Trial.
J Clin Oncol. 2025;43:2059-2068.
PubMed
Abstract available
Reply: Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate
Cancer With Reliable Positive Predictive Value.
J Urol. 2025 Jun 20:101097JU0000000000004634. doi: 10.1097/JU.0000000000004634.
PubMed
Defining Abnormal Prostate Specific Antigen Values for Prostate Cancer Screening
in the Spinal Cord Injury Population.
J Urol. 2025 Jun 17:101097JU0000000000004644. doi: 10.1097/JU.0000000000004644.
PubMed
Abstract available
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic
body radiotherapy for prostate cancer (PACE-C): early toxicity results from a
randomised, open-label, phase 3, non-inferiority trial.
Lancet Oncol. 2025 Jun 12:S1470-2045(25)00205.
PubMed
Abstract available
CONTACT-02 and beyond: rethinking immunotherapy strategies in metastatic prostate
cancer.
Lancet Oncol. 2025 Jun 13:S1470-2045(25)00266.
PubMed
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final
analyses from a phase 3, open-label, randomised trial.
Lancet Oncol. 2025 Jun 13:S1470-2045(25)00209.
PubMed
Abstract available
Novel synthetic peptide-based vaccine shows promise against prostate cancer.
Mol Ther Oncol. 2025;33:201000.
PubMed
Acupuncture to reduce nocturia in survivors of prostate cancer.
Nat Rev Urol. 2025 Jun 16. doi: 10.1038/s41585-025-01059.
PubMed
Optimizing Radiation Therapy for Localized Prostate Cancer: Exploring Synergies
With Androgen Deprivation Therapy and Novel Systemic Agents.
Semin Radiat Oncol. 2025;35:474-487.
PubMed
Abstract available
Radiopharmaceuticals in Prostate Cancer: General Considerations and Utility in
Combination With EBRT.
Semin Radiat Oncol. 2025;35:463-473.
PubMed
Abstract available
Radiotherapy for High-Risk Prostate Cancer.
Semin Radiat Oncol. 2025;35:301-303.
PubMed
Health Disparities and Inequities in Prostate Cancer Along the Continuum of Care.
Semin Radiat Oncol. 2025;35:304-316.
PubMed
Abstract available
PSMA-PET Guided Radiotherapy in Prostate Cancer: A Critical Review of Current
Applications and Future Directions.
Semin Radiat Oncol. 2025;35:317-324.
PubMed
Abstract available
Novel biomarkers for guiding treatment for prostate cancer.
Semin Radiat Oncol. 2025;35:325-332.
PubMed
Abstract available
Hypofractionation/Ultra-hypofractionation for Prostate Cancer Radiotherapy.
Semin Radiat Oncol. 2025;35:333-341.
PubMed
Abstract available
Advancing Prostate Cancer Treatment: A Review of CT and MR-Guided Online Adaptive
Radiotherapy Techniques.
Semin Radiat Oncol. 2025;35:342-352.
PubMed
Abstract available
The Use of Particle Therapy in Prostate Cancer.
Semin Radiat Oncol. 2025;35:353-361.
PubMed
Abstract available
Radiation Therapy in Node-Positive Prostate Cancer: Current Evidence and Future
Directions.
Semin Radiat Oncol. 2025;35:362-373.
PubMed
Abstract available
Elective Regional Nodal Irradiation in Prostate Cancer.
Semin Radiat Oncol. 2025;35:374-384.
PubMed
Abstract available
Debate 1: Radical Prostatectomy For the Right Patient With High-Risk Prostate
Cancer.
Semin Radiat Oncol. 2025;35:385-392.
PubMed
Abstract available
Debate 1: High-Risk Localized Prostate Cancer: Why Combination Hormone Therapy
and Radiotherapy is the Optimal Treatment Strategy for Most Men.
Semin Radiat Oncol. 2025;35:393-401.
PubMed
Abstract available
Debate 2: Primary Localized Prostate Cancer: The Case for Whole-Gland
Brachytherapy Boost.
Semin Radiat Oncol. 2025;35:402-414.
PubMed
Abstract available
Debate 2: The Case for Focal External Beam Radiation Therapy Boost Over
Brachytherapy Boost for Prostate Cancer.
Semin Radiat Oncol. 2025;35:415-422.
PubMed
Abstract available
Debate 3: Metastasis Directed Therapy in Oligometastatic Prostate Cancer.
Semin Radiat Oncol. 2025;35:423-432.
PubMed
Abstract available
Debate 3: Oligometastatic Hormone Sensitive Prostate Cancer Management: Systemic
Therapy Approach.
Semin Radiat Oncol. 2025;35:433-438.
PubMed
Abstract available
Postoperative Radiation Therapy and Controversies Regarding Hormonal Therapy in
the Management of Prostate Cancer.
Semin Radiat Oncol. 2025;35:439-449.
PubMed
Abstract available
The Evolving Management of Radiorecurrent Prostate Cancer.
Semin Radiat Oncol. 2025;35:450-462.
PubMed
Abstract available
Thank you for your interest in scientific medicine.